The Bombay Bar Association canteen has temporarily closed its doors following a court inquiry into the Food and Drug Administration's inspection practices [1].
The closure occurs as the Bombay High Court examines whether FDA officials have been conducting selective checks on hotels and food establishments [1]. This scrutiny highlights potential inconsistencies in how health and safety regulations are enforced across different sectors of the city.
The incident follows a court session where the judiciary questioned the FDA regarding the nature of its regulatory visits [1]. The timing of the canteen closure on Thursday, July 30, 2026 [1], has drawn attention to the relationship between legal associations and regulatory bodies.
Representatives for the Bombay Bar Association addressed the shutdown, saying that the move was not a result of legal mandates. A BBA spokesperson said "the decision to temporarily discontinue its services was taken voluntarily, and not driven by any adverse order from the" court [1].
While the BBA maintains the closure was a self-directed choice, the event takes place amidst a broader judicial review of the FDA's operational transparency [1]. The court's focus remains on whether certain establishments are being targeted, while others are ignored, during safety audits [1].
The canteen remains shut for now as the association manages its internal operations [1]. The FDA has not yet provided a detailed public response to the court's specific questions regarding the selectivity of its hotel checks [1].
“The Bombay Bar Association canteen has temporarily closed its doors.”
This situation underscores a tension between regulatory enforcement and the legal community in Bombay. By questioning the FDA on 'selective checks,' the High Court is signaling a demand for standardized, non-discriminatory application of health codes. The voluntary closure of the BBA canteen, occurring immediately after this judicial scrutiny, suggests a preemptive effort by the association to avoid becoming a focal point of the FDA's current regulatory volatility.
